Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

NCT02236715 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1039

Last updated 2014-09-11

No results posted yet for this study

Summary

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Atrovent®

Sponsors & Collaborators

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2000-02-29

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236715 on ClinicalTrials.gov